10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - 10x Genomics reported revenue of $172.91 million for the quarter ended June 2025, reflecting a year-over-year increase of 12.9% and surpassing the Zacks Consensus Estimate of $139.44 million by 24% [1] - The company achieved an EPS of $0.28, a significant improvement from -$0.32 in the same quarter last year, resulting in an EPS surprise of 180% compared to the consensus estimate of -$0.35 [1] Revenue Breakdown - Consumables revenue reached $122.19 million, slightly above the average estimate of $117.21 million, but showing a year-over-year decline of 1% [4] - Instruments revenue was reported at $14.5 million, below the average estimate of $14.9 million, marking a substantial year-over-year decrease of 39.2% [4] - Chromium instruments generated $5.73 million, slightly exceeding the estimated $5.6 million [4] - Services revenue amounted to $8.48 million, outperforming the estimate of $7.36 million, and reflecting a year-over-year increase of 43.9% [4] - Consumables from Chromium totaled $85.79 million, surpassing the estimate of $84.35 million [4] - Spatial consumables revenue was reported at $36.4 million, exceeding the average estimate of $32.86 million [4] - Spatial instruments revenue was $8.77 million, below the average estimate of $9.3 million [4] Stock Performance - Over the past month, shares of 10x Genomics have returned +4.6%, outperforming the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]